Corning Jere Pharmaceutical -B (09966): JSKN003 is approved by FDA as a breakthrough therapy for treating PROC

The Zhtng Finance and Economics APP News, ConnoGen Pharmaceuticals-B (09966) announced that JSKN003 has been granted a Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration ("FDA") for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (collectively referred to as "PROC") in adult patients who have previously received treatment with the monoclonal antibody trastuzumab and have HER2 overexpression (IHC 1+, 2+, and 3+).